跳至主要内容
临床试验/NCT00143195
NCT00143195已完成4 期

Open Label Study Comparing Amlodipine vs Long-acting Nitrates in Patients With Chronic Stable Angina.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.13 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2001年4月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
200
试验地点
13
主要终点
Evaluate the time to 1mm ST depression

研究概览

简要总结

The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients > =18 years of age with diagnosed clinically stable angina pectoris

排除标准

  • Patients with congestive heart failure, clinically significant cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG

结局指标

主要结局

Evaluate the time to 1mm ST depression

次要结局

  • The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验